Page URL:

Setback for Down syndrome prenatal blood test

12 May 2009
Appeared in BioNews 507

The effectiveness of a prenatal test for Down syndrome has been thrown into doubt after its developers, Sequenom, admitted that study data had been 'mishandled' by its employees. The company, which had been producing apparently strong results in house for its DNA and RNA blood testing products, has now made clear that the results of these studies are not to be relied upon.

The loss of confidence in the test was clearly reflected in the market's response, with shares in the company collapsing from $14.91 to $3.62. In response to the employee misconduct, which has resulted in four suspensions, the company reported itself to both the Food and Drugs Administration and the Securities and Exchange Commission. The test itself, called SEQure Dx, was considered to be central to the company's success and had been due to be launched in June, but investors must now wait for results of independent clinical trials not due to be completed until early 2010.

The discredited in house trials had indicated that SEQure DX could detect the presence of Down syndrome in 96.6 per cent of cases and could predict the absence of Down syndrome with 100 per cent accuracy. The strength of these, non-peer-reviewed, results had raised questions about their reliability, concerns that have now been clearly substantiated.

The resulting delay in the availability of the test is a setback not just for the company but also for health services and patients who are waiting in anticipation for what has been hailed as a safer, less invasive and cheaper alternative to currently available testing procedures (principally CVS, chorionic villus sampling and amniocentesis). Whether SEQure DX is actually of comparable accuracy to these existing procedures is now a question for independent inquiry.

The new external trial will involve 15,000 women, rather than the mere 858 involved in the Sequenom trials. The independent tests will run concurrently with another Sequenom trial, aiming to vindicate the validity of their previous tests, with that trial hoping to yield results before the end of the year. Whatever the findings, however, any production ready test had been delayed by at least twelve to eighteen months and, for now, the credibility of Sequenom and in-house trials have been significantly undermined.

Data 'mishandling' stalls Down's syndrome test
Nature |  6 May 2009
Sequenom Discloses Mishandling of Test Data; Shares Plummet
Genome Web |  30 April 2009
Sequenom shares plummet after delay of Downs test
Forbes |  30 April 2009
Sequenom Shrs Dn On Mishandled Down Syndrome Test Data
Wall Street Journal |  30 April 2009
22 June 2015 - by Ceri Durham 
A US federal appeals court has upheld a ruling that Sequenom's prenatal MaterniT21 test is not sufficiently 'inventive' to be patentable....
10 December 2012 - by Dr Lux Fatimathas 
More sensitive prenatal testing of fetal DNA could improve the detection of genetic diseases, studies find...
26 November 2012 - by Dr Lux Fatimathas 
Non-invasive pre-natal screening for certain abnormalities in fetal chromosomes should be offered to at-risks mothers, recommends the American College of Obstetricians and Gynecologists...
24 October 2011 - by Julianna Photopoulos 
A new prenatal test that can detect Down's syndrome by using a sample of the mother's blood was launched in twenty US cities last Monday....
1 November 2009 - by Nienke Korsten 
According to figures published in the British Medical Journal last week, the number of diagnoses of Down syndrome in babies and fetuses in England and Wales has risen by 71 per cent over the past 20 years. This is attributed to an increase in maternal age over this period. A concurrent increase in terminations of affected pregnancies as a result of improved prenatal screening methods has meant that numbers of live births with Down syndrome have fallen by one per cent, whereas they would have ...
27 October 2008 - by Sheila Briggs 
Political debates are often successfully waged by how one names the issue. In such instances the substantive moral concerns may become obscured and distorted. The so-called 'right-to-life' movement has pressed for the recognition of the rights of the 'unborn child' from the moment of conception. Although this movement has not...
10 June 2002 - by BioNews 
The UK Consumers' Association and GeneWatch UK, an independent genetics watchdog, have welcomed a decision by 13 of the UK's largest high-street retailers not to sell genetic test kits for use at home by the public. Boots, Waitrose, John Lewis, Holland and Barrett and Marks and Spencers are among the...
27 November 2000 - by BioNews 
Scientists at the Chinese University of Hong Kong have developed an accurate, non-invasive test to identify Down's syndrome, using fetal cells present in the mother's blood. The researchers, who reported their results in last week's issue of The Lancet, successfully used the new technique to identify three fetuses affected by...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.